
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The parents of a 2-year-old girl mentioned that once or twice a day over the last few months, when she gets tired, she crosses her legs and leans over as if she has abdominal pain.






